1Z2MAP1O, also known as 1-(indolizin-3-yl)-2-(methylamino)propan-1-one, is a monoamine releasing agent and serotonin receptor modulator and an indolizine derivative.

[1] Conversely, its activity as a norepinephrine releasing agent was not reported, and it was inactive at the remaining sites of the 47 screened targets.

[1] The drug's EC50Tooltip half-maximal effective concentration values for induction of monoamine release were 109 nM for serotonin and 227 nM for dopamine in Chinese hamster ovary (CHO) cells expressing the human monoamine transporters (MATs).

[1] 1Z2MAP1O's inhibition of the serotonin transporter (SERT) was not reported.

[1] 1Z2MAP1O was patented by Matthew Baggott and Tactogen in 2023.